Investigating the Potential Effects of 6PPDQ on Prostate Cancer Through Network Toxicology and Molecular Docking

Overview

Journal Toxics

Date 2025 Jan 8

PMID 39771106

Authors

Yuanzhi Song

Wuhong Weng

Shengde Wu

Affiliations

Soon will be listed here.

Abstract

(1) Background: N-(1,3-Dimethylbutyl)-N'-phenyl-p-phenylenediamine-quinone (6PPDQ), as a newly discovered environmental toxin, has been found more frequently in our living conditions. The literature reports that damage to the reproductive and cardiovascular system is associated with exposure to 6PPDQ. However, the relationship between 6PPDQ and cancer still requires more investigation. This research aims to investigate the association between 6PPDQ and prostate cancer. (2) Methods and Results: Based on the data retrieved from the Pharmmapper, CTD, SEA, SwissTargetPrediction, GeneCard, and OMIM databases, we summarized 239 potential targets utilizing the Venn tool. Through the STRING network database and Cytoscape software, we constructed a PPI network and confirmed ten core targets, including IGF1R, PIK3R1, PTPN11, EGFR, SRC, GRB2, JAK2, SOS1, KDR, and IRS1. We identified the potential pathways through which 6PPDQ acts on these core targets using Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) analyses. Ultimately, through molecular docking methods, 6PPDQ binds closely with these ten core targets. These findings indicate that 6PPDQ may influence the proteins related to prostate cancer and may be linked to prostate cancer via several known signaling pathways. (3) Conclusions: This article employs innovative network toxicology to elucidate the prostate carcinogenic effects of 6PPDQ through its modulation of specific vital genes and signaling pathways, thereby establishing a foundational platform for future investigations into the impact of 6PPDQ on prostate cancer and potentially other tumors.

References

Perner F, Perner C, Ernst T, Heidel F . Roles of JAK2 in Aging, Inflammation, Hematopoiesis and Malignant Transformation. Cells. 2019; 8(8). PMC: 6721738. DOI: 10.3390/cells8080854. View

Goetz J, Lajoie P, Wiseman S, Nabi I . Caveolin-1 in tumor progression: the good, the bad and the ugly. Cancer Metastasis Rev. 2008; 27(4):715-35. DOI: 10.1007/s10555-008-9160-9. View

Zhang Z, Xu X, Qian Z, Zhong Q, Wang Q, Hylkema M . Association between 6PPD-quinone exposure and BMI, influenza, and diarrhea in children. Environ Res. 2024; 247:118201. DOI: 10.1016/j.envres.2024.118201. View

Zhuang L, Lin J, Lu M, Solomon K, Freeman M . Cholesterol-rich lipid rafts mediate akt-regulated survival in prostate cancer cells. Cancer Res. 2002; 62(8):2227-31. View

Chen D, Hou X . Aspartame carcinogenic potential revealed through network toxicology and molecular docking insights. Sci Rep. 2024; 14(1):11492. PMC: 11106323. DOI: 10.1038/s41598-024-62461-w. View

Ban K, Feng S, Shao L, Ittmann M . RET Signaling in Prostate Cancer. Clin Cancer Res. 2017; 23(16):4885-4896. PMC: 5609835. DOI: 10.1158/1078-0432.CCR-17-0528. View

Dou M, Zhou X, Fan Z, Ding X, Li L, Wang S . Clinical Significance of Retinoic Acid Receptor Beta Promoter Methylation in Prostate Cancer: A Meta-Analysis. Cell Physiol Biochem. 2018; 45(6):2497-2505. DOI: 10.1159/000488268. View

Wang X, Shen Y, Wang S, Li S, Zhang W, Liu X . PharmMapper 2017 update: a web server for potential drug target identification with a comprehensive target pharmacophore database. Nucleic Acids Res. 2017; 45(W1):W356-W360. PMC: 5793840. DOI: 10.1093/nar/gkx374. View

McKusick V . Mendelian Inheritance in Man and its online version, OMIM. Am J Hum Genet. 2007; 80(4):588-604. PMC: 1852721. DOI: 10.1086/514346. View

10.

Powers G, Marker P . Recent advances in prostate development and links to prostatic diseases. Wiley Interdiscip Rev Syst Biol Med. 2013; 5(2):243-56. PMC: 3583581. DOI: 10.1002/wsbm.1208. View

11.

Xiong W, Huang C, Deng H, Jian C, Zen C, Ye K . Oncogenic non-coding RNA NEAT1 promotes the prostate cancer cell growth through the SRC3/IGF1R/AKT pathway. Int J Biochem Cell Biol. 2017; 94:125-132. DOI: 10.1016/j.biocel.2017.12.005. View

12.

Song J, Song Y, Guo W, Jia J, Jin Y, Bai A . Regulatory roles of KDR antisense oligonucleotide on the proliferation of human prostate cancer cell line PC-3. J BUON. 2014; 19(3):770-4. View

13.

Sherman B, Hao M, Qiu J, Jiao X, Baseler M, Lane H . DAVID: a web server for functional enrichment analysis and functional annotation of gene lists (2021 update). Nucleic Acids Res. 2022; 50(W1):W216-W221. PMC: 9252805. DOI: 10.1093/nar/gkac194. View

14.

Wan X, Liang G, Wang D . Potential human health risk of the emerging environmental contaminant 6-PPD quinone. Sci Total Environ. 2024; 949:175057. DOI: 10.1016/j.scitotenv.2024.175057. View

15.

Dahiya R, Park H, Cusick J, Vessella R, Fournier G, Narayan P . Inhibition of tumorigenic potential and prostate-specific antigen expression in LNCaP human prostate cancer cell line by 13-cis-retinoic acid. Int J Cancer. 1994; 59(1):126-32. DOI: 10.1002/ijc.2910590122. View

16.

Ahmed Z, Timsah Z, Suen K, Cook N, Lee 4th G, Lin C . Grb2 monomer-dimer equilibrium determines normal versus oncogenic function. Nat Commun. 2015; 6:7354. PMC: 4491180. DOI: 10.1038/ncomms8354. View

17.

Keiser M, Roth B, Armbruster B, Ernsberger P, Irwin J, Shoichet B . Relating protein pharmacology by ligand chemistry. Nat Biotechnol. 2007; 25(2):197-206. DOI: 10.1038/nbt1284. View

18.

Unterberger C, Maklakova V, Lazar M, Arneson P, Mcilwain S, Tsourkas P . GH Action in Prostate Cancer Cells Promotes Proliferation, Limits Apoptosis, and Regulates Cancer-related Gene Expression. Endocrinology. 2022; 163(5). PMC: 8995093. DOI: 10.1210/endocr/bqac031. View

19.

Stelzer G, Rosen N, Plaschkes I, Zimmerman S, Twik M, Fishilevich S . The GeneCards Suite: From Gene Data Mining to Disease Genome Sequence Analyses. Curr Protoc Bioinformatics. 2016; 54:1.30.1-1.30.33. DOI: 10.1002/cpbi.5. View

20.

Kanagasabai T, Li G, Shen T, Gladoun N, Castillo-Martin M, Celada S . MicroRNA-21 deficiency suppresses prostate cancer progression through downregulation of the IRS1-SREBP-1 signaling pathway. Cancer Lett. 2021; 525:46-54. DOI: 10.1016/j.canlet.2021.09.041. View